Login / Signup

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.

Yukihiro ToiShunichi SugawaraYosuke KawashimaTomoiki AibaSachiko KawanaRyohei SaitoKyoji TsurumiKana SuzukiHisashi ShimizuJun SugisakaHirotaka OnoYutaka DomekiKeisuke TerayamaAtsushi NakamuraShinsuke YamandaYuichiro KimuraYoshihiro Honda
Published in: The oncologist (2018)
Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study evaluted whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer. Results showed that the objective response rate and progression-free survival were significantly better in the patients who developed irAEs than in the patients who did not develop irAEs, and the incidence of irAEs and positivity for antithyroid antibody at pretreatment were independent predictors of treatment response of nivolumab monotherapy. Therefore, the development of irAEs predicts clinical benefit and suggests that cautious management of irAEs can lead to achieving maximum clinical benefit from nivolumab monotherapy.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • free survival
  • combination therapy
  • open label
  • randomized controlled trial
  • tyrosine kinase